- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
USFDA investigates death of another infant given Abbott formula: Bloomberg
The FDA also inspected the facility in February and March and found unsanitary conditions that led the plant to shut down until Abbott could fix the problems.
New Delhi: U.S. Food and Drug Administration officials are investigating the death of another infant who was given formula made by Abbott Laboratories.
The infant died in January and the FDA was notified June 10, according to a statement Wednesday.
"The investigation of this most recent consumer complaint is in its preliminary stages and the agency will provide an update as it learns more," the FDA said.
Abbott shares shed some gains on the news and were up 1.2% at 3:36 p.m. in New York.
Abbott recalled formula, including widely used Similac, in February after four babies became ill after consuming products made at the company's plant in Sturgis, Mich. Two of the infants died.
Read also: Abbott to release some nutrition products halted after baby formula recall
The FDA said it hasn't been able to definitively determine whether Abbott's formula was the reason for the illnesses or deaths. Abbott has said there is no conclusive evidence to link its formula to the illnesses or deaths.
The FDA also inspected the facility in February and March and found unsanitary conditions that led the plant to shut down until Abbott could fix the problems. The plant reopened earlier this month only to be beset by flood waters that halted its infant formula production last week.
Read also: Abbott labs India unit concludes recall of baby formula products manufactured at Michigan facility
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751